raloxifene hydrochloride has been researched along with Urinary Bladder Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoffman, KL; Lerner, SP; Smith, CL | 1 |
| Ayala, GE; Hsieh, JT; Jian, W; Kim, IY; Lerner, SP; Shen, SS; Smith, CL; Sonpavde, G; Younes, M; Yu, J | 1 |
| Jang, JJ; Kim, BC; Kim, HT; Kim, IY; Kim, SJ; Mamura, M; Seong, DH | 1 |
3 other study(ies) available for raloxifene hydrochloride and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
Topics: Apoptosis; Carcinoma, Transitional Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Immediate-Early Proteins; MCF-7 Cells; Poly(ADP-ribose) Polymerases; Raloxifene Hydrochloride; S-Phase Kinase-Associated Proteins; Tamoxifen; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Microarray Analysis; Neoplasm Staging; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Urinary Bladder Neoplasms | 2006 |
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Carrier Proteins; Caspase 3; Caspases; Cell Division; Cell Membrane; Cell Nucleus; Cycloheximide; Cytochrome c Group; DNA Fragmentation; Dose-Response Relationship, Drug; Estrogen Receptor Modulators; Humans; In Situ Nick-End Labeling; Membrane Potentials; Mitochondria; Phosphorylation; Protein Binding; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2; Raloxifene Hydrochloride; Retroviridae; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2002 |